New EU report voices fresh concern over AMR
Fresh concern has been voiced about the impact of use of antibiotics on the increase in antibiotic-resistant bacteria.
Fresh concern has been voiced about AMR | Photo credit: Fotolia
A new report from the European Food Safety Authority, the European Medicines Agency and the European Centre for Disease Prevention and Control presents new data on antibiotic consumption and antibiotic resistance and reflects improved surveillance across Europe.
Reacting to the reports, Vytenis Andriukaitis, European Commissioner for health and food safety, said, "To contain antibiotic resistance we need to fight on three fronts at the same time: human, animal and the environment.
"This is exactly what we are trying to achieve in the EU and globally with our recently launched EU action plan on antimicrobial resistance.
"This new report confirms the link between antibiotic consumption and antibiotic resistance in both humans and food-producing animals."
The joint interagency antimicrobial consumption and resistance analysis (JIACRA) reports state that there are still important differences across the EU in the use of antibiotics in animals and humans.
Reducing their unnecessary use will have an impact on the occurrence of resistance, say the three agencies.
Overall antibiotic use is higher in food-producing animals than in humans, but the situation varies across countries and according to the antibiotics, according to the reports.
In particular, a class of antibiotics called polymyxins - which includes colistin - is used widely in the veterinary sector. It is also increasingly used in hospitals to treat multidrug-resistant infections.
Other antibiotics are more often used in humans than in animals. These include third- and fourth-generation cephalosporins and quinolones, antibiotics that are also considered critically important for human health.
The report also notes that resistance to quinolones, used to treat salmonellosis and campylobacteriosis in humans, is associated with use of antibiotics in animals.
The agencies say that the use of third and fourth generation cephalosporins for the treatment of infections caused by E.coli and other bacteria in humans is associated with resistance to these antibiotics in E.coli found in humans.
The report is the result of close cooperation between the three EU agencies, each drawing on their specific expertise and data from monitoring of antibiotic resistance and antibiotic consumption in animals and humans.
The conclusions are in line with those of their first report on the issue published in 2015. However, they say that the availability of better quality data allowed for a more sophisticated analysis.
Experts from the three agencies are now recommending further research to better understand how the use of antibiotics and resistance affect one another.
Early intervention is a cost-effective solution to reducing the burden of musculoskeletal disorders, writes Juan Jover.
A balanced approach to data protection in research will boost patient health, writes Richard Bergström.
Innovation and R&D are the keys to a healthier future, explains Nathalie Moll.